AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAR 6 - (NewsRx.com & NewsRx.net) -- VaxGen, Inc., (VXGN) announced the hiring of two professionals with distinguished track records to help the company submit its AIDS vaccine for regulatory approval if the vaccine, AIDSVAX, proves effective approximately 12 months from now.
VaxGen named Carmen M. Betancourt vice president of regulatory affairs and quality assurance. Betancourt has 24 years of experience in biologics and the biotechnology industry, 14 of which have been spent in regulatory affairs. She served most recently as vice president, Regulatory Affairs, at Titan Pharmaceuticals, where she managed multiple product development programs supporting the clinical investigation of pharmaceutical products. Prior to joining Titan, she held regulatory positions at Genentech, Coulter Pharmaceutical, and Bayer.
At VaxGen, Betancourt will be the company's primary liaison with the U.S. Food and Drug Administration and will oversee the preparation of a biologics license application (BLA) for AIDSVAX if it proves effective at the end of ongoing Phase III trials. She will fulfill the same role for any other ...